EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study

Tao Huang, Zhimin Fan, Yongsheng Wang, Xi Yan, Hongjian Yang, Shu Wang, Da Pang, Huiping Li, Haibo Wang, Cuizhi Geng, Liang Huang, Yaqing Sun, Bei Wang, Guofang Sun, Asna Siddiqui, Eleonora Restuccia, Zhimin Shao

International Journal of Clinical Oncology · 2026-07 · 31 (7) · 1189-1200

DOI: 10.1007/s10147-025-02935-7 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Neoadjuvant fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) demonstrated non-inferior cycle 7 pertuzumab and trastuzumab serum trough concentrations (C trough ), and similar total pathological complete response (tpCR) rates and safety, to intravenous pertuzumab plus trastuzumab (P + H IV) in HER2-positive early breast cancer (eBC). In the FDChina study (NCT04024462), we assessed neoadjuvant–adjuvant PH FDC SC vs. P + H IV in Chinese patients with HER2-positive eBC. Methods Patients received four doxorubicin (60 mg/m 2 ) plus cyclophosphamide (600 mg/m 2 ), then four docetaxel (75–100 mg/m 2 ) cycles, every 3 weeks. Patients were randomized 1:1 to PH FDC SC (loading: 1200 mg pertuzumab/600 mg trastuzumab; maintenance: 600 mg/600 mg) or P + H IV (loading: 840 mg/8 mg/kg; maintenance: 420 mg/6 mg/kg) alongside docetaxel before surgery. Patients then continued HER2-targeted therapy for 14 cycles. Co-primary non-inferiority endpoints: cycle 7 pertuzumab and trastuzumab C trough . Secondary endpoints: tpCR, long-term efficacy, safety. Results The lower bounds of the 90% confidence intervals of pertuzumab and trastuzumab cycle 7 geometric mean ratios (0.99 and 1.44, respectively) exceeded the pre-specified non-inferiority margin (0.8). tpCR rates were 55.6% for PH FDC SC vs. 56.4% for P + H IV. Grade ≥ 3 adverse events occurred in 72% vs. 69% of patients. Conclusion The study met the co-primary endpoints of non-inferiority of cycle 7 serum C trough for pertuzumab and trastuzumab for PH FDC SC vs. P + H IV. tpCR rates and safety were comparable between arms. PH FDC SC may be a viable treatment option for Chinese patients with HER2-positive eBC.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →